Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 15/20 | 0.48 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124097 | 0.89 | APEX1 (0.52) | DHODHMBNL1ACHEPIK3CAAPEX1 | |
| SCHEMBL2123397 | 0.89 | PIK3CA (0.42) | DHODHDHFRALKBH5ACHEPIK3CA | |
| SCHEMBL13063651 | 0.87 | MBNL1 (0.51) | DHODHMBNL1DHFRALKBH5ACHE | |
| SCHEMBL2712142 | 0.86 | MBNL1 (0.50) | DHODHMBNL1DHFRALKBH5PIK3CA | |
| SCHEMBL2123544 | 0.85 | ADORA2A (0.53) | DHODHMBNL1DHFRALKBH5 | |
| SCHEMBL2712560 | 0.84 | PDE2A (0.46) | DHODHMBNL1APEX1 | |
| SCHEMBL2124157 | 0.84 | ACHE (0.43) | DHODHDHFRALKBH5ACHEPIK3CA | |
| SCHEMBL2124964 | 0.84 | TDO2 (0.47) | DHODHACHEPIK3CA | |
| SCHEMBL2712579 | 0.83 | LMNA (0.51) | DHODHMBNL1DHFRALKBH5APEX1 | |
| SCHEMBL2123517 | 0.82 | PIK3CA (0.49) | DHODHDHFRALKBH5ACHEPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | DHODH 2656/4885MBNL1 1806/4885DHFR 3632/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | DHODH 3503/4885MBNL1 1476/4885DHFR 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.